COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria
NCT ID: NCT00123903
Last Updated: 2017-01-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
1220 participants
INTERVENTIONAL
2005-07-31
2006-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
COREG MR Versus TOPROL-XL On The Lipid Profile Of Normolipidemic Or Mildly Dyslipidemic Patients With Hypertension
NCT00273052
A Study to Compare COREG CR to COREG CR Fixed-dose Combination in Patients With High Blood Pressure
NCT00537043
Research Study To Test Carvedilol CR + Lisinopril Versus Lisinopril + Placebo In Patients With High Blood Pressure
NCT00624065
The COREG And Lisinopril Combination Therapy In Hypertensive Subjects (COSMOS) Trial
NCT00347360
The Vascular Effects of Carvedilol Controlled Release (CR) in Abdominally Obese Hypertensive Patients
NCT00459056
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
metoprolol xl
carvedilol MR
lisinopril
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must have been taking an ACE (angiotensin converting enzyme) inhibitor either alone or as part of an antihypertensive regimen for at least 8 weeks.
* Persistent microalbuminuria.
Exclusion Criteria
* Has been taking any non-ocular beta-blockers for any indication within three months prior to Pre-screening.
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Birmingham, Alabama, United States
GSK Investigational Site
Mobile, Alabama, United States
GSK Investigational Site
Phoenix, Arizona, United States
GSK Investigational Site
Fullerton, California, United States
GSK Investigational Site
Inglewood, California, United States
GSK Investigational Site
Los Angeles, California, United States
GSK Investigational Site
Mission Viejo, California, United States
GSK Investigational Site
Oakland, California, United States
GSK Investigational Site
Redondo Beach, California, United States
GSK Investigational Site
Colorado Springs, Colorado, United States
GSK Investigational Site
Hollywood, Florida, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Pembroke Pines, Florida, United States
GSK Investigational Site
Sarasota, Florida, United States
GSK Investigational Site
Tampa, Florida, United States
GSK Investigational Site
Decatur, Georgia, United States
GSK Investigational Site
Chicago, Illinois, United States
GSK Investigational Site
Chicago, Illinois, United States
GSK Investigational Site
Melrose Park, Illinois, United States
GSK Investigational Site
Avon, Indiana, United States
GSK Investigational Site
Elkhart, Indiana, United States
GSK Investigational Site
Evansville, Indiana, United States
GSK Investigational Site
Evansville, Indiana, United States
GSK Investigational Site
Indianapolis, Indiana, United States
GSK Investigational Site
Indianapolis, Indiana, United States
GSK Investigational Site
Lafayette, Louisiana, United States
GSK Investigational Site
Ayer, Massachusetts, United States
GSK Investigational Site
Worcester, Massachusetts, United States
GSK Investigational Site
Las Vegas, Nevada, United States
GSK Investigational Site
Voorhees Township, New Jersey, United States
GSK Investigational Site
Buffalo, New York, United States
GSK Investigational Site
Camillus, New York, United States
GSK Investigational Site
East Syracuse, New York, United States
GSK Investigational Site
Kingston, New York, United States
GSK Investigational Site
Port Chester, New York, United States
GSK Investigational Site
Rochester, New York, United States
GSK Investigational Site
Charlotte, North Carolina, United States
GSK Investigational Site
Greensboro, North Carolina, United States
GSK Investigational Site
Raleigh, North Carolina, United States
GSK Investigational Site
Cleveland, Ohio, United States
GSK Investigational Site
Columbus, Ohio, United States
GSK Investigational Site
Kettering, Ohio, United States
GSK Investigational Site
Oklahoma City, Oklahoma, United States
GSK Investigational Site
Oregon City, Oregon, United States
GSK Investigational Site
Beaver, Pennsylvania, United States
GSK Investigational Site
Havertown, Pennsylvania, United States
GSK Investigational Site
Philadelphia, Pennsylvania, United States
GSK Investigational Site
Reading, Pennsylvania, United States
GSK Investigational Site
West Grove, Pennsylvania, United States
GSK Investigational Site
East Providence, Rhode Island, United States
GSK Investigational Site
Greer, South Carolina, United States
GSK Investigational Site
Orangeburg, South Carolina, United States
GSK Investigational Site
Johnson City, Tennessee, United States
GSK Investigational Site
Beaumont, Texas, United States
GSK Investigational Site
Dallas, Texas, United States
GSK Investigational Site
Dallas, Texas, United States
GSK Investigational Site
Fort Worth, Texas, United States
GSK Investigational Site
Galveston, Texas, United States
GSK Investigational Site
Houston, Texas, United States
GSK Investigational Site
Houston, Texas, United States
GSK Investigational Site
Midland, Texas, United States
GSK Investigational Site
San Antonio, Texas, United States
GSK Investigational Site
San Antonio, Texas, United States
GSK Investigational Site
Burke, Virginia, United States
GSK Investigational Site
Springfield, Virginia, United States
GSK Investigational Site
Edmonds, Washington, United States
GSK Investigational Site
Olympia, Washington, United States
GSK Investigational Site
Spokane, Washington, United States
GSK Investigational Site
Spokane, Washington, United States
GSK Investigational Site
Spokane, Washington, United States
GSK Investigational Site
Wenatchee, Washington, United States
GSK Investigational Site
Calgary, Alberta, Canada
GSK Investigational Site
New Westminster, British Columbia, Canada
GSK Investigational Site
Vancouver, British Columbia, Canada
GSK Investigational Site
Winnipeg, Manitoba, Canada
GSK Investigational Site
Winnipeg, Manitoba, Canada
GSK Investigational Site
Bay Roberts, Newfoundland and Labrador, Canada
GSK Investigational Site
Brampton, Ontario, Canada
GSK Investigational Site
Hamilton, Ontario, Canada
GSK Investigational Site
Kitchener, Ontario, Canada
GSK Investigational Site
London, Ontario, Canada
GSK Investigational Site
Stoney Creek, Ontario, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Charlottetown, Prince Edward Island, Canada
GSK Investigational Site
Montague, Prince Edward Island, Canada
GSK Investigational Site
Bonaventure, Quebec, Canada
GSK Investigational Site
Mirabel, Quebec, Canada
GSK Investigational Site
Montreal, Quebec, Canada
GSK Investigational Site
Pointe-Claire, Quebec, Canada
GSK Investigational Site
Saint Romuald, Quebec, Canada
GSK Investigational Site
Trois-Rivières, Quebec, Canada
GSK Investigational Site
Río Grande, Puerto Rico, Puerto Rico
GSK Investigational Site
San Juan, Puerto Rico, Puerto Rico
Countries
Review the countries where the study has at least one active or historical site.
Study Documents
Access uploaded study-related documents such as protocols, statistical analysis plans, or lay summaries.
Document Type: Informed Consent Form
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Clinical Study Report
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Dataset Specification
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Statistical Analysis Plan
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Annotated Case Report Form
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Study Protocol
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentDocument Type: Individual Participant Data Set
For additional information about this study please refer to the GSK Clinical Study Register
View DocumentRelated Links
Access external resources that provide additional context or updates about the study.
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COR103560
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.